Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

NIFUROXAZIDE CRS (10 MG)

NIFUROXAZIDE CRS (10 MG)

965-52-6

DISCOVER
TRIAMTERENE CRS (10 MG)

TRIAMTERENE CRS (10 MG)

396-01-0

DISCOVER
DOXEPIN HYDROCHLORIDE CRS (5 MG)

DOXEPIN HYDROCHLORIDE CRS (5 MG)

1229-29-4

DISCOVER
Iobenguane sulfate - reference spectrum, Qty : n/a

Iobenguane sulfate - reference spectrum, Qty : n/a

NA

DISCOVER
ACEMETACIN IMPURITY MIXTURE CRS (0.06 MG)

ACEMETACIN IMPURITY MIXTURE CRS (0.06 MG)

53164-05-9

DISCOVER
ALTIZIDE IMPURITY B CRS (15 MG)

ALTIZIDE IMPURITY B CRS (15 MG)

NA

DISCOVER
ATROPINE FOR PEAK IDENTIFICATION CRS (0.25 MG)

ATROPINE FOR PEAK IDENTIFICATION CRS (0.25 MG)

51-55-8

DISCOVER
CARPROFEN CRS (30 MG)

CARPROFEN CRS (30 MG)

53716-49-7

DISCOVER
CLOPAMIDE FOR SYSTEM SUITABILITY CRS (10 MG)

CLOPAMIDE FOR SYSTEM SUITABILITY CRS (10 MG)

636-54-4

DISCOVER
CLOTRIMAZOLE FOR PEAK IDENTIFICATION CRS (1.005 MG)

CLOTRIMAZOLE FOR PEAK IDENTIFICATION CRS (1.005 MG)

23593-75-1

DISCOVER
DOXEPIN FOR SYSTEM SUITABILITY CRS (1 MG)

DOXEPIN FOR SYSTEM SUITABILITY CRS (1 MG)

1229-29-4

DISCOVER
ESTRADIOL BENZOATE FOR SYSTEMSUITABILITY CRS (10 MG)

ESTRADIOL BENZOATE FOR SYSTEMSUITABILITY CRS (10 MG)

50-50-0

DISCOVER